Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) by Diessner, J. et al.
OPEN
Targeting of preexisting and induced breast cancer
stem cells with trastuzumab and trastuzumab
emtansine (T-DM1)
J Diessner*,1, V Bruttel1, RG Stein1,2, E Horn1, SF M Ha¨usler1,3, J Dietl1, A Ho¨nig1,3 and J Wischhusen*,1,3
The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive
breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to
an insufficient targeting of the CD44highCD24low breast cancer stem cell subset, which is not only highly resistant to
chemotherapy and radiotherapy but also a poor target for trastuzumab due to low HER2 surface expression. Hence, we explored
whether the new antibody-drug conjugate T-DM1, which consists of the potent chemotherapeutic DM1 coupled to trastuzumab,
could improve the targeting of these tumor-initiating or metastasis-initiating cells. To this aim, primary HER2-overexpressing
tumor cells as well as HER2-positive and HER2-negative breast cancer cell lines were treated with T-DM1, and effects on survival,
colony formation, gene and protein expression as well as antibody internalization were assessed. This revealed that
CD44highCD24lowHER2low stem cell-like breast cancer cells show high endocytic activity and are thus particularly sensitive
towards the antibody-drug conjugate T-DM1. Consequently, preexisting CD44highCD24low cancer stem cells were depleted by
concentrations of T-DM1 that did not affect the bulk of the tumor cells. Likewise, colony formation was efficiently suppressed.
Moreover, when tumor cells were cocultured with natural killer cells, antibody-dependent cell-mediated cytotoxicity was
enhanced, and EMT-mediated induction of stem cell-like properties was prevented in differentiated tumor cells. Thus our study
reveals an unanticipated targeting of stem cell-like breast cancer cells by T-DM1 that may contribute to the clinical efficacy of this
recently approved antibody-drug conjugate.
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The Her-2/neu (c-erbB2, HER2) proto-oncogene is a trans-
membrane receptor tyrosine kinase1 that mediates critical
cellular functions like growth, differentiation and survival in
malignant and normal breast epithelial cells. Homodimeriza-
tion of HER2 as well as heterodimerization of HER2 with the
related receptors HER1/EGFR1/ErbB1, HER3 or HER4
triggers oncogenic signaling.2,3 Overexpression of the HER2
gene is associated with an aggressive clinical phenotype,
increased disease recurrence and unfavorable prognosis.4
Although 20–30% of breast cancers show HER2 amplifica-
tion, genome-wide sequencing has revealed activating HER2
mutations as an alternative mechanism for HER2 activation in
breast cancer.5 Moreover, cancer stem cell (CSCs) were
found to overexpress HER2 even in breast cancers not
classified as HER2-positive.6 Thus HER2-directed treatments
could be beneficial for numerous patients.
The humanized monoclonal antibody trastuzumab
(Herceptin, Genentech), which binds to the extracellular
domain of HER2, was found to reverse many oncogenic
effects caused by the overexpression of HER2. In patients
with HER2-positive breast and gastric cancer, trastuzumab
could thus significantly improve disease-free and overall
survival in the adjuvant and metastasized setting.7–9
Used as monotherapy, trastuzumab inhibits tumor cell
growth. In combination with chemotherapeutics or ionizing
radiation, duration of response and progression-free
survival are improved.10,11
Mechanistically, trastuzumab does not block only signal
transduction via the HER2 receptor and its interaction
partners. By binding to HER2-overexpressing target cells,
trastuzumab also ‘labels’ tumor cells for recognition by
immune effectors like natural killer (NK) cells. These bind
antibodies via Fcg-receptors, which then trigger the so-called
‘antibody-dependent cell-mediated cytotoxicity’ (ADCC).12,13
The functional relevance of NK cell recruitment for the activity
of trastuzumab is supported by a clinical correlation between
NK cell function and therapeutic response,12 by a loss of
activity in Fcg-RIIIA knockout animals mice14 and by an
improved in vivo effect of trastuzumab upon additional NK cell
stimulation.15 Importantly, the Fcg-part of trastuzumab, which
mediates these immune-stimulatory effects, was retained in
trastuzumab emtansine (T-DM1).
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In preliminary studies, we have already demonstrated the
induction of NK cell–mediated ADCC by trastuzumab in vitro.
Moreover, we could provide in vivo evidence that HER2-
positive cells surviving an ADCC challenge with NK cells and
trastuzumab preferentially show a ‘CSC-like’ phenotype.16
CSCs or tumor-initiating or metastasis-initiating cells are, in
breast cancer, characterized by a CD44highCD24low pheno-
type, expression of ganglioside GD2, aldehyde dehydrogenase 1
(ALDH), high clonogenicity, high tumorigenicity and increased
metastatic potential.17–19 Current concepts suggest that CSCs
often resist cytotoxic treatments and are therefore responsible
for recurrence.20,21 Moreover, recent data indicate that stress
stimuli,22 unsuccessful treatments23 and inflammation24–26 can
trigger the conversion of (partly) differentiated cancer cells
towards a CSC-like phenotype. The underlying process that is
known as ‘epithelial-to-mesenchymal transition’ (EMT) enables
transformation of epithelial into highly mobile mesenchymal
cells, which is required for embryonic development. In cancer,
however, highly mobile cells that have lost their epithelial
phenotype may cause metastasis.
A promising new tool for the treatment of HER2-positive
breast cancer is the antibody-drug conjugate T-DM1.
It consists of the antibody trastuzumab and the potent
Maytansine-derivative DM1, which inhibits cell division and
induces cell death27 by blocking the spindle apparatus.28,29
Due to its high toxicity as free drug and low activity at tolerated
levels, Maytansine requires a specific targeting to become
applicable for antitumor therapy.30–33 DM1 was thus
chemically linked to trastuzumab with a drug-to-antibody ratio
of 3.5 : 1.31 HER2 represents an excellent target for an
antibody-drug conjugate as it is highly overexpressed on
HER2-positive cancer cells34 and also found on CSCs in
tumors that do not show general positivity for HER2.6 After
binding to HER2, T-DM1 is internalized by endocytosis and
degraded in lysosomes, causing the release of the active
metabolite DM1.35
Importantly, the mechanisms of action of trastuzumab
(such as ADCC and the blockade of HER2-specific signaling)
are preserved in the T-DM1 conjugate, but the targeted
delivery of a highly toxic chemotherapeutic to HER2-positive
tumor cells provides an additional benefit that has already
yielded impressive clinical results in the first studies.36 In this
set of experiments, we now investigated whether the new
HER2-specific antibody-drug conjugate T-DM1 could also
improve the targeting of CSCs.
Results
T-DM1 induces dose- and time-dependent cell death
in HER2-positive tumor cells. To quantify the surface
expression of HER2, six breast cancer cell lines (BT-474,
SK-BR-3, MCF-7, MDA-MB-231, HCC1806 and HCC1937)
were either enzymatically detached with Accutase or
mechanically scraped before being stained with trastuzumab
followed by a Cy5-conjugated detection antibody. Irrespec-
tive of the mode of harvesting, quantification by flow
cytometry (Figure 1a) confirmed high levels of HER2 on
BT474 and SK-BR-3 cells (commonly classified as
HER2þþþ ) and revealed significant HER2 surface
expression on MCF-7 and MDA-MB-231 cells, whereas
HCC1806 and HCC1937 cells were negative for HER2.
Considering that the common description of MCF-7 and
MDA-MB-231 as HER20/þ 37 is based on analysis by
immunohistochemistry (compare Table 1), we presume that
flow cytometric analysis is more sensitive. In fact, several
previous studies could also show that HER2 represents a
possible target in MCF-7 cells.6,38
Next, the sensitivity of HER2high (SK-BR-3 and BT474),
HER2þ (MCF-7 and MDA-MB-231) and HER2 (HCC1806
and HCC1937) breast cancer cell lines towards T-DM1 was
tested over 96 h. Light microscopy showed that dead cells
round off and detach. Cell density could thus be determined by
crystal violet staining and used as a surrogate parameter for
cell death (Figure 1b). Data were confirmed by the metabolic
WST-1 assay (not shown). Finally, the effect of HER2-specific
therapeutics on breast cancer cells was assessed by cell
cycle analysis. After staining of the cellular DNA with
propidium iodide, cell cycle arrest is typically indicated by an
increase of cells in G0/G1 or G2/M-phase, and cell death is
evidenced by the appearance of a sub-G0 fraction (Figure 1c).
In all three assays, T-DM1 dose-dependently induced cell
death in HER2-expressing breast cancer cells but not in the
HER2-negative triple-negative breast cancer cell lines
HCC1806 and HCC1937. Likewise, we could not detect any
significant effect of T-DM1 on primary lymphocytes, which are
HER2-negative (data not shown). This confirmed that
cytotoxic effects of T-DM1 are HER2 dependent. Trastuzu-
mab, in contrast, had hardly any influence on cell cycle
distribution or cell density in our assays (Figure 1c and data
not shown).
T-DM1 efficiently suppresses clonogenicity of breast
cancer cells, even though HER2 surface expression
is low on the CD44highCD24low CSC subset. Rather
than acute cytotoxicity, colony formation is often a better
in vitro test for the efficacy of anti-cancer drugs.39 Following
48 h of incubation with T-DM1, HER2-positive breast
cancer cell lines like SK-BR-3 and BT-474 dose-dependently
lost their clonogenic potential (Figure 2a), which suggests
a selective depletion of clonogenic cells and thus a
Figure 1 T-DM1 is toxic for HER2-positive tumor cells. (a) HER2 expression levels on MCF-7, MDA-MB-231, BT-474, SK-BR-3, HCC1937 and HCC1806 cells were
assessed by flow cytometry using trastuzumab followed by a Cy5-conjugated anti-human detection antibody. Specific fluorescence intensities (SFIs) were calculated by
dividing the median fluorescence obtained with the HER2-specific antibody by the mean fluorescence obtained with an equally labeled isotype control antibody of irrelevant
specificity. Black curve: isotype control antibody (10 mg/ml), red curve: HER2 expression. (b) A total of 1 105 breast cancer cells per well were seeded in a 96-well plate and
treated with the indicated concentrations of T-DM1. After 96 h, cell density was determined by crystal violet staining. All measurements were performed in triplicates. (c) Breast
cancer cells were either left untreated (left panel) or treated with 10 mg/ml trastuzumab (middle) or 10mg/ml T-DM1 (right panel) for 48 h. Cell cycle distribution was then
assessed via DNA staining with propidium iodide followed by FACS analysis. The region representing the subG0 phase, that is, dead cells, is shaded in red, the Go/G1 peak is
marked in green and the G2/M phase in blue. Representative experiments are shown (nZ3 for all experiments)
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preferential targeting of CSC39 by T-DM1. Trastuzumab, in
contrast, had no such effect.
To confirm this hypothesis, we used MCF-7 cells from which
a highly aggressive and poorly immunogenic40 CD44high
CD24low CSC-like subset16,17 can be purified. Treatment of
either unsorted MCF-7 cells or of purified CD44highCD24low
cells did not only show the higher clonogenicity of this
subpopulation but also confirmed the strong effect of T-DM1
on the clonogenicity of HER2-positive breast cancer cells
(Figure 2b, upper panel). Similar data were obtained with
MDA-MB-231 cells (Figure 2b, lower panel). Trastuzumab, in
contrast, did not inhibit clonogenicity. For BT-474 and SK-BR-
3 cells, flow cytometric or magnetic bead-based enrichment of
the CD44highCD24low subpopulation failed that precluded their
use in this assay.
As T-DM1 concentrationsr100 ng/ml almost abrogated
clonogenicity in SK-BR-3, BT-474 and MCF-7 cells, we
compared EC50 values for clonogenicity and cytotoxicity for
all 6 cell lines (Figure 2c). The striking differences between
these values show that T-DM1 preferentially targets clono-
genic cells rather than the bulk of the tumor cell population.
Again, HER2 positivity was a prerequisite for a discernible
effect of T-DM1.
Importantly, clonogenicity (which, depending on the cell
line, ranged from 5% to 26%) can be used as a surrogate
marker for CSCs. Our own previous findings, however, had
shown lower HER2 surface expression on the CD44high
CD24low presumed stem cell-like subset than on their more
differentiated counterparts.41 In line with this observation,
stem cell-like CD44highCD24lowHER2low cells escaped from
targeting with trastuzumab and NK cells.16 The reduced
HER2 surface expression on CD44highCD24low cells was also
now confirmed with primary tumor cells obtained from pleural
effusions of five patients with metastasized HER2-positive
breast cancer (Figure 2d and data not shown).
Effect of T-DM1 in the presence of NK cells. The
therapeutic effect of anti-HER2 antibody treatment was
found to correlate with the recruitment of NK cells in to the
tumor microenvironment12 and to depend on both innate and
adaptive immunity.42 One important mechanism is ADCC,16
which we found to be similar for trastuzumab and T-DM1
(Figure 3a). However, recruitment of immune cells into a
tumor and inflammation can also promote EMT, which leads
to dedifferentiation of cancer cells towards a CSC-like
phenotype.24–26 In fact, coculture of MCF-7 breast cancer
cells with NK cells did not induce morphological changes
toward an elongated fibroblast-like shape,43,44 thereby
indicating the transition from an epithelial to a mesenchymal
phenotype (Figure 3b). Cell surface expression of the
epithelial adherence factor E-Cadherin also decreased
(Figure 3c). Western blotting revealed the induction of
b-Catenin, Vimentin and (non-junctional) Claudin-145
(Figure 3d), which have been described during EMT. The
characteristic transcription factors for EMT, Twist, Snail and
Slug could, unfortunately, not be visualized by immuno-
blotting that may be due to their low and transient expression
in MCF-7 cells. However, qRT-PCR analysis showed an
induction of these factors on mRNA level that could be
prevented by T-DM1 (Figure 3e). Accordingly, immune-
mediated induction of EMT could be prevented by T-DM1.
Effect of T-DM1 on induced breast CSCs. When T cells26
or NK cells16 induce EMT in breast cancer cells, induction of
CSC-like properties can be the unwanted consequence. In
line with these findings, coculture with NK cells increased the
proportion of CD44highCD24low cells in the MCF-7 cell line
(Figure 4a). As an additional control, use of the ALDEFLUOR
reagent system19 confirmed both stem cell induction in
coculture with NK cells and the prevention of this effect
by T-DM1 (Figure 4b). The enrichment of cells with a
CSC signature was reflected by enhanced clonogenicity
(Figure 4c). Both these effects could, again, be prevented by
addition of T-DM1 to the cocultures, whereas trastuzumab
showed no such effect (Figures 4a–c and data not shown).
Similar data were also obtained in other cell lines (shown for
SK-BR-3 in Figures 4d and e). Accordingly, T-DM1 seems to
be able to block the immune-mediated induction of tumor
stem cells.
Maintenance of the CD44highCD24low breast CSC
phenotype requires autophagy. Our data show that the
HER2-specific antibody-drug conjugate T-DM1 exerts strong
effects on preexisting (Figure 2b) and induced (Figure 4a)
CD44highCD24low breast cancer CSCs, even though HER2
surface levels are low on this target cell population (Figure 2d).
This apparent contradiction might be resolved by considering
the high level of autophagy exerted by these cells. In fact,
Table 1 Characteristics of breast cancer cell lines and primary patient-derived breast cancer cell cultures
Age of
patient
Estrogen
rez.
Progesterone
rez.
Origin of cells Primary tumor Ethnicity Specific
fluorescence
indices (SFI) of
HER2
Immuno
histochemical
index (ICH)
MCF-7 69 Positive Positive Pleural effusion Invasive ductal carcinoma Caucasian 82 0–1þ 37
SK-BR-3 43 Negative Negative Pleural effusion Invasive ductal carcinoma Caucasian 1142 3þ 37
BT474 60 Positive Positive Solid tumor Invasive ductal carcinoma Caucasian 1191 3þ 37
MDA-MB-231 51 Negative Negative Pleural effusion Invasive ductal carcinoma Caucasian 97 0–1þ 37
HCC1937 23 Negative Negative Pleural effusion Invasive ductal carcinoma Caucasian 1.1
HCC1806 60 Negative Negative Solid tumor Invasive ductal carcinoma Caucasian 1.3
Pat. 1 55 Negative Negative Pleural effusion Invasive ductal carcinoma Caucasian 3þ
Pat. 2 72 Positive Negative Pleural effusion Invasive ductal carcinoma Caucasian 3þ
Pat. 3 68 Positive Negative Pleural effusion Invasive ductal carcinoma Caucasian 3þ
Pat. 4 66 Positive Positive Pleural effusion Invasive ductal carcinoma Caucasian 3þ
Pat. 5 76 Positive Positive Pleural effusion Invasive ductal carcinoma Caucasian 3þ
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autophagy was reported to be critical for the tumorigenicity
of breast cancer stem-like/progenitor cells46–48 and found
to positively regulate the CD44highCD24low phenotype.49
In order to exclude artifacts depending on side effects of
autophagy inhibitors, we used three different substances
(3-methyl adenine, chloroquine and artesunate), which all
Figure 2 Preferential targeting of clonogenic breast cancer cells by T-DM1. (a) HER2-positive breast cancer cells (left: SK-BR-3, right: BT-474) were treated for 48 h with
different concentrations of trastuzumab and T-DM1. Afterwards, clonogenicity of surviving tumor cells was analyzed by plating 100 and 500 viable cells. Three weeks later,
colonies were first visualized by staining with crystal violet and then counted. The clonogenicity index corresponds to the percentage of cells that showed the ability to form new
colonies. (b) CD44highCD24low breast cancer stem cells were isolated from the MCF-7 (upper panel) or MDA-MB-231 (lower panel) cell lines via FACS sorting. Subsequently,
the clonogenicity of the unsorted and of the sorted cells was analyzed in the presence of different concentrations of trastuzumab or T-DM1. The error bars indicate the S.D.
(n¼ 3). In panels (a and b), P-values versus untreated control were calculated by two-sided, unpaired Student’s t-test (*Po0.05, **Po0.01). (c) HER2-positive and -negative
breast cancer cell lines were treated with different concentrations of T-DM1 for 48 h to obtain EC50 values for clonogenicity and cytotoxicity. Using concentrations up to 10mg/ml,
the EC50 values for HCC1806 and HCC1937 cells were not attained. (d) HER2 expression was analyzed by flow cytometry on CD44
highCD24high and CD44highCD24low cells
from a patient with metastasized HER2-positive breast cancer. Green curve: isotype control antibodies (10 mg/ml), red curve: HER2 expression on CD44highCD24low cells, blue
curve: HER2 expression on CD44highCD24high cells (10 mg/ml). CD24high and CD24low cell populations were separated by gating and showed similar binding of the isotype
control antibody. The indicated values for the specific fluorescence intensities (SFIs) were obtained by dividing the signal obtained with the specific antibody by the signal
obtained with the corresponding isotype control. Please note the logarithmic scale
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Figure 3 During coculture with NK cells, T-DM1 can induce ADCC in breast cancer cells and inhibit EMT. (a) HCC1806, SK-BR-3 or MCF-7 breast cancer cells were
cocultured with NK cells for 4 h, at a tumor-to-NK cell ratio of 1 : 2. For better discrimination, immune cells were stained with eFluor 670Cell Proliferation Dye, and tumor cells
were stained with CFSE. Target cell lysis of breast cancer cells (as evidenced by CFSE loss) was determined after 4 h by FACS analysis. Normal human immunoglobulins G
(IgGs) served as a control for the humanized antibody trastuzumab and its conjugate T-DM1 (all used at 50 ng/ml). Data analysis was performed using an unpaired, two-sided
Student’s t-test. Results from three independent experiments were analyzed (*Po0.05, **Po0.01). (b) MCF-7 breast cancer cells were photographed before (left panel) and
after (right panel) 16 h coculture with NK cells to visualize the changes regarding cellular morphology from the epithelial to a fibroblastic shape. (c) Flow cytometry was used to
determine E-cadherin surface expression on MCF-7 breast cancer cells before and after 24 h of coculture with NK cells. Although the binding of a PerCP/Cy5.5-labeled isotype
control of irrelevant specificity remained unaltered after coculture (green curve), the signals obtained with a similarly labeled anti-E-Cadherin antibody (clone 67A4) before and
after coculture are shown in blue (before) and red (after), respectively. SFI values are indicated. (d) MCF-7 breast cancer cells were incubated for 24 h with NK cells, using a
tumor cell-to-NK cell ratio of 1 : 2. After removal of non-adherent (i.e., NK) cells, protein lysates were prepared from the remaining adherent MCF-7 cells and tested for
expression of b-catenin, vimentin and claudin by western blotting. b-Actin was used as a loading control. (e) Cocultures were set up as in panel (d). Where indicated, T-DM1
was added at a concentration of 50 ng/ml. After 16 h, NK cells were removed by washing, and RNA was extracted from the remaining adherent MCF-7 cells. The regulation of
EMT markers was analyzed by Sybr-Green-based quantitative real-time PCR, using 18S rRNA as internal control
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caused an accumulation of the macroautophagy substrates
LC3-II and p62 in MCF-7 cells. Quantification of the obtained
western blotting data showed the strongest effect with
chloroquine and a somewhat weaker efficiency for
3-methyladenine (Figure 5a). Consequently, 3-methylade-
nine,50 chloroquine51 and artesunate52 all reduced the size of
the CD44highCD24low population (Figure 5b) and the clono-
genicity of MCF-7 cells (Figure 5c), up to a complete loss of
clonogenicity and of CD44highCD24low cells in the absence of
acute cytotoxicity. Using artesunate, similar data were also
obtained with primary breast cancer cells from pleural
effusions (Figure 5d).
CD44highCD24low breast CSCs show increased autop-
hagy leading to enhanced internalization of HER2 from
the cell surface. Interestingly, it has already been hypothe-
sized that autophagy might facilitate resistance against the
small molecule HER2 receptor kinase inhibitor Lapatinib in
HER2-positive breast cancer cells.53 Thus, we wondered
whether the low HER2 surface levels on CD44highCD24low
Figure 4 T-DM1 blocks the immune-mediated enrichment of CD44highCD24low and ALDHþ breast cancer CSCs. (a–e) MCF-7 (a–c) and SK-BR-3 (d and e) breast
cancer cells were cocultured with NK cells for 16 h, using a tumor cell-to-NK cell ratio of 1 : 2. Trastuzumab or T-DM1 was added where indicated. (a and d) Using
fluorescently labeled antibodies against CD24 and CD44, the size of the CD44highCD24low population was analyzed before and after incubation with polyclonal NK cells. In
panel (b), the proportion of ALDH-expressing cells was assessed before (grey) and after (black) coculture with NK cells using the ALDEFLUOR reagent system. Cells
displaying high levels of ALDH are identified via the enzymatic conversion of a fluorogenic dye that can be visualized by flow cytometry. Positivity in this assay is considered
to be a characteristic trait of CSCs. In panels (a, b and d), representative experiments are shown. (c and e) MCF-7 (upper bar chart) and SK-BR-3 (lower bar chart) breast
cancer cells were incubated for 16 h with NK cells, using a tumor cell-to-NK cell ratio of 1 : 2. T-DM1 or trastuzumab were added at the indicated concentrations. After 16 h,
clonogenicity of the surviving tumor cells was assessed as in Figure 2b. Clonogenicity indices for cells that had not been cocultured with NK cells are shown in grey.
P-values for the effects of trastuzumab or T-DM1 were calculated by the two-sided unpaired Student’s t-test using the respective coculture without antibody as relevant
control (n¼ 3, **Po0.01)
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cells might be due to increased internalization of the
receptor, which is a phenomenon known to occur in response
to receptor activation.35 In line with this hypothesis, we
observed a loss of the CD24lowHER2low subpopulation when
autophagy was inhibited. HER2 expression on CD24high
cells, however, remained unaltered (data not shown).
We thus assessed the internalization of the HER2 surface
antigen in CD44highCD24high and CD44highCD24low cells
using trastuzumab labeled with the fluorogenic dye pHrodo.
This pH-dependent dye experiences a steep increase in
fluorescence upon acidification. As clathrin-coated or other
vesicles used for endocytosis are characterized by a
low pH, this provided us with a tool to visualize internaliza-
tion of the conjugated anti-HER2 antibody. Co-staining of
trastuzumab-pHrodo-treated cells after 6 h confirmed
that450% of the CD44highCD24low cells, but only o2% of
the more differentiated CD44highCD24high cells, internalized
pHrodo-labeled trastuzumab. Internalization could be
prevented by addition of artesunate (Figure 6a). Irrespective
of the tumor cell subset, no internalization was observed
Figure 5 Enhanced autophagy is an essential requirement for clonogenic CD44highCD24low stem cell-like breast cancer cells. (a–c) MCF-7 breast cancer cells were
incubated with the autophagy inhibitors 3-methyladenine, chloroquine and artesunate for 24 h. (a) Cell lysates were prepared from untreated and treated MCF-7 breast cancer
cells and assayed for the expression of LC3-II and p62. b-Actin served as a loading control. Signals were quantified using Image J (U.S. National Institutes of Health,
Bethesda, MD, USA; http://imagej.nih.gov/ij/), normalized to b-actin and the relative increase in non-degraded LC3-II and p62 was calculated. (b) The size of the
CD44highCD24low CSC population was analyzed by flow cytometry before and after treatment. (c) MCF-7 breast cancer cells were treated with different concentrations of
3-methyladenine, chloroquine and artesunate for 24 h. Thereafter, the ability of viable cells to form new colonies was analyzed as in Figure 2b (*Po0.05, **Po0.01).
(d) Primary tumor cells obtained from a pleural effusion of a patient with metastasized HER2-positive breast cancer, treated with different concentrations of artesunate and
analyzed by flow cytometry for the presence of a CD44highCD24low CSC population
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with the non-binding Rituximab-pHrodo conjugate (data
not shown).
To further confirm that maintenance of the CD44high
CD24low CSC-like state and internalization of pHrodo-labeled
trastuzumab by these cells depends on autophagy, we sought
to inhibit autophagy by siRNAs against Beclin and LC3
(Figure 6b). Although downregulation of these essential
mediators of autophagy was incomplete, siRNA treatment
was still sufficient to reduce the extent of the CD44highCD24low
population and the percentage of pHrodo-positive cells
(Figure 6c). The fact that the remaining CD44highCD24low
cells showed a hardly reduced uptake of pHrodo might
suggest that the loss of the CD24low signature precedes or
coincides with the reduced level of internalization.
Figure 6 Internalization by increased autophagy represents an ‘Achilles’ heel’ of CSCs with regard to T-DM1. (a) The HER2-specific antibody trastuzumab was labeled
with the fluorogenic dye pHrodo. pHrodo shows a strong fluorescence in the FL-2H channel once the pH of its surroundings becomes more acidic, for example, upon
internalization in endocytotic vesicles. Shown is the fluorescent signal from internalized trastuzumab-pHrodo against CD24 in CD44high cells, with CD44highCD24low
cells representing the stem cell-like cancer cell population. Upper left: control MCF-7 cells, upper right: MCF-7 cells were incubated with pHrodo-labeled immunoglobulin
G1 (IgG1) isotype control antibodies and counter-stained with anti-CD24-FITC. Lower left: MCF-7 cells were incubated with pHrodo-labeled trastuzumab and stained with
anti-CD24-FITC. Lower right: MCF-7 cells were incubated with pHrodo-labeled trastuzumab in the presence of the autophagy inhibitor artesunate (20 mg/ml) and stained with
anti-CD24-FITC. Bar chart: Under the various applied conditions, the respective percentage of trastuzumab-pHrodo-internalizing cells was determined and evaluated
separately for the CD24high and CD24low subsets. (b) Using TransIT TKO transfection reagent, MCF-7 breast cancer cells were transfected with 25 nM of siRNA against Beclin
(BECN1 no. s16537, Ambion) or LC3 (no. MAP1LC3A, Ambion) or with a universal negative siRNA control (Sigma). Forty-eight hours later, cells were lysed and the expression
of Beclin, LC3 and b-actin was assayed in the various groups by western blotting. (c) MCF-7 cells were transfected with siRNA as in panel (c) before being incubated with
trastuzumab-pHrodoas in panel (a). Staining for CD44 and CD24 followed by flow cytometric analysis enabled the quantification of CD44highCD24low cells, of trastuzumab-
internalising pHrodopos cells and of pHrodopos CD24low cells shown in panel (c)
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Importantly, as pHrodo and emtansine are similarly small in
size, and as they are both coupled to the same large antibody,
it may be assumed that T-DM1 will show a similar behavior as
this fluorogenic conjugate. We thus propose that CD44high
CD24low breast cancer CSCs show a high level of internaliza-
tion with regard to HER2 and thus evade effector mechan-
isms, such as ADCC. However, by this same property these
cells will preferentially internalize antibody-drug conjugates.
This can not only explain the highly efficient targeting of
clonogenic CD44highCD24low cells by T-DM1 but also provide
a more general rationale for the targeting of breast cancer
CSCs with antibody-drug conjugates against HER2 or other
oncogenic growth factor receptors.
Discussion
The HER2-specific antibody trastuzumab10 has significantly
increased overall survival in patients suffering from HER2-
positive breast cancer. Moreover, a recent study has also
revealed a role for HER2 in the CSC subset of cell lines
(including MCF-7) which are not commonly classified
as HER2 overexpressing.6 Likewise, synergy between
trastuzumab and paclitaxel or docetaxel had also been
reported in such cell lines.38 Accordingly, more patients than
previously anticipated might benefit from treatment with
anti-HER2 antibodies. Unfortunately, however, the majority
of patients treated with trastuzumab experience relapse at
some time after treatment. Thus, a better understanding of the
mechanism(s) underlying this resistance might pave the way
towards more effective strategies. In our previous studies, we
could demonstrate in vitro that the binding of trastuzumab
‘labels’ HER2-positive breast cancer cells for Fcg-dependent
recognition by NK cells,16 thereby inducing ADCC.12,13 This
important immune-stimulatory effect has been preserved in
the antibody-drug conjugate T-DM1, which has retained the
Fcg-part of trastuzumab (Figure 3a). Also inhibition of HER2
signaling, as evidenced by reduced activation of the phos-
phatidylinositol 30-kinase-AKT pathway, is similarly achieved
by both trastuzumab and T-DM1 (data not shown). However,
T-DM1 combines the mechanisms of action of trastuzumab
with the additional specific application of the potent
chemotherapeutic DM1.31,32
Unlike trastuzumab, T-DM1 thus induced cell cycle arrest
and significant cell death in HER2-positive tumor cells that is
likely due to the toxin DM1 contained in T-DM1. EC50 values
over 48 h were mostlyZ10 mg/ml (Figures 1b and c), which
might be hard to achieve in patients. Using clinically relevant
concentrations (3mg/ml)54 of T-DM1, a significant proportion
of target cells survived in vitro that could point towards
chemoresistance. However, HER2-positive tumor cells
surviving a treatment with T-DM1 displayed drastically
reduced clonogenicity (Figures 2a–c), even at T-DM1
concentrations as low as 50 ng/ml. Likewise, T-DM1 incuba-
tion almost abrogated the clonogenicity of sorted CD44high
CD24low cells, whereas trastuzumab treatment showed no
comparable effect on this highly tumorigenic and poorly
immunogenic subset (Figure 2b). This suggests that T-DM1 is
far more effective against CSC than trastuzumab. In fact, the
major limitation encountered in our previous study was the
insufficient targeting of CD44highCD24lowHER2low cells
either with trastuzumab alone or in conjunction with NK
cells.16 Based on the evidence that this subset possesses
characteristics of the so-called ‘tumor-initiating’ or ‘metasta-
sis-initiating’ or ‘CSCs’,17 a lack of activity against this
subpopulation may explain the high rate of recurrence after
treatment.
CSCs, however, constitute a rather dynamic subset. We
and others have observed26 that ‘unproductive’ (i.e., non-lytic)
interactions between immune and tumor cells induce EMT
in breast cancer cells, which reprograms previously differ-
entiated cancer cells towards a CSC-like phenotype.22
Accordingly, tumor cell cultures that had interacted with NK
cells showed morphological changes towards a mesenchymal
phenotype (Figure 3b), downregulation of the epithelial cell
adhesion molecule E-Cadherin (Figure 3c), upregulation of
EMT markers (Figures 3d and e), more CD44highCD24low
(Figures 4a and d) and ALDHþ (Figure 4b) cells and
enhanced clonogenicity (Figures 4c and e). Addition of
T-DM1 to the coculture, however, prevented this expansion
of the CSC population (Figures 3e and 4). This left us with two
possible explanations: either tumor cells that had survived the
treatment were ‘sufficiently damaged’ to lose all stem cell-like
properties or the antibody-drug conjugate might preferentially
target highly clonogenic ‘CSCs’ - in spite of their low HER2
surface expression (Figure 2d). This prompted us to
investigate the possibility of enhanced internalization by
CSCs. In fact, the CSC phenotype has repeatedly been
linked to autophagy,49,55,56 a tightly regulated catabolic
process involving the degradation of a cell’s own components
through the lysosomal machinery. On the one hand, auto-
phagy helps to keep up a balance between degradation,
synthesis and recycling of cellular products and allows
stressed or starving cells to recycle nutrients from unneces-
sary processes to more essential metabolic tasks. On the
other hand, autophagy leads to a constant recycling of cellular
components and thus enables longevity57 and maintenance of
a stem cell-like phenotype not only in hematopoietic58 but also
in breast cancer CSCs.48 In line with these reports, autophagy
inhibitors (chloroquine, 3’-methyladenine or artesunate)51,59
abrogated CD44highCD24lowHer2low cells and clonogenicity in
primary breast cancer cells from pleural effusions and in
breast cancer cell lines (Figures 5b and d). Most importantly,
however, we measured internalization of trastuzumab by
covalently coupling the fluorogenic dye pHrodo to the
antibody. This revealed a preferential internalization of the
conjugated anti-HER2 antibody by CD44highCD24low cells that
could be abrogated by inhibiting autophagy (Figure 6a).
Unspecific binding via the pHrodo moiety or the human IgG
backbone was excluded by use of the pHrodo-labeled
humanized anti-CD20 antibody rituximab. The link between
autophagy, CD44highCD24low CSC and internalization of
labeled trastuzumab was further confirmed by siRNA-
mediated downregulation of LC3 or Beclin (Figure 6b), which
resulted in a significantly smaller CD44highCD24low CSC
subset and in reduced internalization of pHrodo-labeled
trastuzumab. Interestingly, those cells that retained the
CD24low phenotype also showed unaltered internalization.
We thus propose that the low HER2 (and, most likely also the
low CD24) surface expression on CD44highCD24low cells is
mainly due to internalization via autophagy. This, once again,
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confirms that autophagy enables constant renewal of these
cells and may be protective against most therapeutic insults,
including immune-mediated destruction via ADCC. However,
when it comes to antibody-drug conjugates, this mechanism
constitutes an ‘Achilles’ heel’ that may be therapeutically
exploited by T-DM1. Considering that the targeting of these
cells is thought to be essential for a successful cancer therapy,
our in vitro data thus suggest that T-DM1 holds great promise
for future treatment of early and metastatic HER2-positive
breast cancer. In fact, first results from the EMILIA trial, a
phase III study in which 991 women with locally advanced or
metastatic, unresectable, trastuzumab- and taxane-treated,
HER2-positive breast cancer were enrolled showed longer
progression-free survival (9.6 versus 6.4 months) and a
superior safety profile for T-DM1 against the combination of
capecitabine with lapatinib.60
Further trials (MARIANNE, TH3RESA) are ongoing. From a
mechanistic point of view, it is interesting to note that a tubulin
inhibitor can prevent the unwanted induction of tumor stem
cell characteristics. In line with this notion, pretreatment of
cancer cells with paclitaxel (Taxol) likewise prevented the
induction of EMT and of stem cell-like features (data not
shown). Thus, tubulin-dependent processes seem to have a
seminal role for CSC induction. It may thus be speculated
whether the induced CD44highCD24low cells actually originate
from more differentiated tumor cells via (induced) asymmetric
cell divisions. In any case, these data show that the coupling of
a potent inhibitor of the mitotic spindle to trastuzumab was a
good choice for T-DM1. Moreover, the combination of the
anti-proliferative and immune-activating effect of trastuzumab
at the cell surface with intracellular delivery of a potent toxin
upon endocytosis could serve as a template for further
antibody-drug conjugates. Such novel therapeutics might
not only be well tolerated but also be particularly effective
against CSCs with their high internalization rate.
Materials and Methods
Cell culture and reagents. MCF-7, MDA-MB-231, BT-474, HCC1937,
HCC1806 and SK-BR-3 breast cancer cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and the Deutsche Sammlung fu¨r
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), authenti-
cated and cultured as indicated by the supplier. Primary tumor cells were obtained
from pleural effusions of patients undergoing puncture for the palliative treatment
of metastasized breast cancer at our institution. Further investigation of these cells
was approved by both the patients and the local ethics committee. Cells were
centrifuged, washed with PBS, and transferred to L-valine-free, D-valine-
containing Dulbecco’s Modified Eagle´s Medium supplemented with 2% heat-
inactivated FCS (Biochrom, Berlin, Germany), penicillin (100 IU/ml) and
streptomycin (100 IU/ml) (all from PAA, Co¨lbe, Germany). Non-adherent cells
were removed by washing after 24 h. Fibroblast growth was suppressed due to the
lack of L-valine. Autophagy inhibitors (3-methyl adenine, artesunate and
chloroquine) were obtained from Sigma (Deisenhofen, Germany).
Cytotoxicity and cell cycle assays. Breast cancer cells were treated with
different concentrations of T-DM1 and trastuzumab as indicated. Cell density after
drug treatment was assessed by crystal violet staining. As this assay is based on
the quantification of adherent cells, microscopy was used to confirm that dying
cells became round and detached. As an additional control, the metabolic WST-1
assay (Roche, Mannheim, Germany) was used according to the manufacturer’s
instructions. For cell cycle analysis, cells were detached, fixed and permeabilized
for at least 1 h in ice-cold 70% ethanol and washed with PBS before their DNA
was stained with propidium iodide (PI). RNA was simultaneously digested with
DNAse-free RNAse A (Carl Roth, Karlsruhe, Germany). PI intercalates into DNA
with no sequence preference and thus enables the assessment of the cellular
DNA content in the FL-2A channel of the FACSCalibur flow cytometer
(BD Biosciences, Heidelberg, Germany). Doublets were excluded via the FL-2W
channel. Cells containing less than a complete set of chromosomes (i.e., 2n) are
considered to be dead.
Clonogenicity assays. Clonogenicity assays are in vitro cell survival assays
based on the ability of single cells to establish a new colony. The assay essentially
investigates the proportion of cells that can undergo ‘unlimited’ division. Breast
cancer cells were treated as indicated before being seeded at low density on
low-attachment plastic material (Greiner BioOne, Frickenhausen, Germany). After
2–3 weeks, colonies were fixed, stained with crystal violet (0.5% w/v) and counted.
Stained colonies consisting of at least 50 cells were visible without the use of a
microscope.
Flow cytometric analysis of surface expression levels and cell
sorting. Cells were either mechanically or enzymatically detached using
Accutase (PAA), blocked and stained with 10 mg/ml Trastuzumab or 10mg/ml
T-DM1 (Genentech, Burlingame, CA, USA) followed by a Cy5-conjugated goat
anti-human IgG (Rockland Immunochemicals, Gilbertsville, PA, USA) detection
antibody. Simultaneously, CD44-RPE (Clone 2BJ18, BioLegend, San Diego, CA,
USA), CD24-FITC (clone SWA-11, kindly provided by Professor Peter Altevogt,
German Cancer Research Centre, Heidelberg, Germany) and the life stain
7-aminoactinomycin D (Sigma) were applied and analyzed on a FACSCalibur or
an Attune flow cytometer (Life Technologies, Darmstadt, Germany). For
E-Cadherin surface staining, a PerCP/Cy5.5-labeled anti-human CD324/E-
Cadherin antibody (Clone 67A4) and a corresponding isotype control (Clone
MOPC-21), both from BioLegend, were used. Where appropriate, expression
levels are indicated as specific fluorescence intensity values, which are obtained
by dividing the fluorescence intensity detected with the specific antibody by the
signal measured with the isotype-matched control antibody. For fluorescence-
activated cell sorting, the stained cells were separated twice on a Digital
FACSVantage (BD Biosciences), first in yield and then in purity mode.
ALDH assay. The ALDEFLUOR assay (STEMCELL Technologies, Grenoble,
France) enables the identification of stem and progenitor cells based on their high
expression of ALDH1. This enzyme converts the fluorogenic substrate BODIPY-
aminoacetaldehyde into a green fluorescent dye that can be visualized by flow
cytometry. As the ALDEFLUOR reaction product will leak out of dead cells, only
viable cells are identified by this assay. Transporter-mediated exclusion of the dye
from stem cells is prevented by multi-drug reporter inhibition with a verapamil-
containing inhibitor contained in the kit. Tumor cells were treated with different
concentrations of drugs for variable intervals of time. Afterwards, the ALDEFLUOR
test was conducted according to the manufacturer’s instructions.
NK cell preparation and cytotoxicity assays. Peripheral blood
lymphocytes were obtained from healthy volunteers by density gradient
centrifugation (Biocoll, Biochrom) and cultured for 8-11 days on irradiated
(30 Gy) RPMI8866 feeder cells to obtain polyclonal NK cell populations (30). NK
cell-mediated lysis of MCF-7 or MDA-MB-231 cells was assessed by modified
fluorometric assessment of T lymphocyte antigen specific lysis assays.41 NK cells
were thus labeled with eFluor 670 Cell Proliferation Dye (ebioscience, Frankfurt,
Germany) while target cells (2 105/well) were stained with carboxyfluorescein
diacetate succinimidyl ester (CFSE) (Invitrogen, Karlsruhe, Germany). Cocultures
were set up using different effector:target ratios, and lytic activity was assessed
after 16 h by flow cytometric detection of CFSEdim cells among the eFluor
670-negative target cell population. Values were corrected for spontaneous
leakage of CFSE.
Immunoblot analysis. Regulation of EMT-related proteins in MCF-7 cells
that had been cocultured with NK cells was analyzed by immunoblot. In short, NK
cells were removed by washing. Adherent cells were detached, collected by
centrifugation, washed with PBS and lysed in protein lysis buffer containing 50 mM
Tris-HCl (tris(hydroxymethyl)aminomethane-hydrochloric acid) pH 8.0 (Sigma)),
120 mM sodium chloride, 5 mM EDTA, 2 mg/ml Aprotinin, 10mg/ml Leupeptin,
1 mM PMSF, 10 nM sodium fluoride (all purchased from Carl Roth, Karlsruhe,
Germany), 0.5% Nonidet P-40 and 1 mM sodium orthovanadate (both from
Applichem GmbH, Darmstadt, Germany). Proteins were separated on 8–15%
polyacrylamide (Carl Roth) gels under reducing conditions, transferred to
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Nitrocellulose (Protran Transfer Membrane, Whatman, Dassel, Germany), which
was blocked in PBS containing 5% skimmed milk powder and 0.05% Tween20
(both from Carl Roth), and incubated overnight at 4 1C with the following
antibodies (all from Cell Signaling Technology, Danvers, MA, USA): anti-human
LC3 (clone D3U4C), anti-human Beclin (clone D40C5), anti-human -Catenin
(clone D10A8), anti-human Claudin (no. 4933), anti-human Vimentin (clone
D21H3), anti-human pAKT (clone Ser473), and anti-human AKT (no. 9272).
Antibodies against p62 (Poly6477) and against b-actin (Poly6221), which served
as loading control, were from BioLegend. Proteins were visualized using
horseradish peroxidase-coupled anti-mouse or anti-rabbit IgG secondary antibody
(Cell Signaling) and homemade enhanced chemiluminescence (ECL) solution.
ECL solution was prepared by mixing 0.25 mg/ml Luminol (Carbosynth Ltd,
Berkshire, UK) in 0.1 M Tris-HCL (pH 8.6) with 1.1 mg/ml para-hydroxycoumaric
acid (Sigma-Aldrich, Taufkirchen, Germany) and 0.03% hydrogen peroxide (Carl
Roth) at a 10 : 1 : 0.003 ratio.
qRT-PCR. Total RNA was prepared using TriFast (Peqlab, Erlangen, Germany)
and transcribed with the iScript cDNA Synthesis kit (Bio-Rad, Munich, Germany).
For real-time PCR, cDNA amplification was monitored using the ABsolute QPCR
SYBR Green Low Rox mix (ABgene, Epsom, UK) on the ABI PRISM 7500
Sequence Detection System (Applied Biosystems, Weiterstadt, Germany). To this
aim, 40 cycles of a two-step PCR protocol (95 1C for 15 s, 60 1C for 1 min) were
performed. The following primers were used:
18S up: 50-CGGCTACCACATCCAAGGAA-30; 18S down: 50-GCTGGAAT
TACCGCGGCT-30; Snail up: 50-CTGCTCCACAAGCACCAAGAGTC-30; Snail
down: 50-CCAGCTGCCCTCCCTCCAC-30; b-actin up: 50-TGTTTGAGACCTT
CAACACCC-30; b-actin down: 50-AGCACTGTGTTGGCGTACAG-30; Slug up:
50-GGGGAGAAGCCTTTTTCT TG-30; Slug down: 50-TCCTCATGTTTGTGCA
GGAG-30; Vimentin up: 50-GAGAATTTGCCGTTGAAGC-30; Vimentin down:
50-GCTTCCTGTAGGTGGCAATC-30; Twist up: 50-GGAGTCCGCAGTCTTA
CGAG-30; Twist down: 50-TCTGGAGGACCTGGTAGAG-30; E-Cadherin up:
50-CCGAGATGGGGTTGATAATG-30; and E-Cadherin down: 50-ACAGTGG
CCACCTACAAAG-30. Data analysis was done using the DDCT method for relative
quantification. Dissociation curves confirmed the presence of a single specific PCR
product.
pHrodo assay. HER2-specific antibodies were labeled with the fluorogenic
dye pHrodo (Life Technologies, INVITROGEN CORPORATION, Burlington, ON,
Canada) according to the manufacturer’s instructions. pHrodo shows increased
fluorescence in the FL-2H channel as the pH of its surroundings becomes more
acidic, for example, upon internalization in endocytotic vesicles. With respect to
breast cancer cells, pHrodo-labeled humanized anti-CD20 antibody Rituximab
(Rituxan) was used as a non-binding control.
siRNA transfection. In all, 2 105 MCF-7 cells were seeded in a six-well
plate. Twenty-four hours later, they were transfected with 25 nM of siRNA against
Beclin (BECN1 no.s16537) or LC3 (MAP1LC3A, no. s39155, both from Ambion,
Life Technologies, Darmstadt, Germany) or with a universal negative siRNA
control (Sigma), using 10ml of TransIT-TKO Transfection Reagent (Mirus,
Madison, WI, USA). Forty-eight hours later, cells were lysed, and the expression
levels of Beclin, LC3 and b-actin were assayed in the various groups by western
blotting. Incubation with trastuzumab-pHrodo and subsequent flow cytometric
analysis were performed as described above.
Statistics. Experiments were performed at least three times with similar
results, and representative experiments are shown. S.Ds. for flow cytometry data
were calculated by using the Summit software (Beckman Coulter, Krefeld,
Germany). Analysis of significance was performed using an unpaired, two-sided
Student’s t-test.
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